01

Retained DisplayTM

The Retained DisplayTM (ReD) platform was developed in-house by Myrio’s founders Ben Kiefel and Matt Beasley. Using a completely different, patent-protected process to other antibody discovery platforms, the speed and flexibility of the platform enables it to find very rare binders against challenging targets.

ReD has been deployed to rapidly screen and isolate neutralizing antibodies specific for SARS-CoV-2.

02

Pipeline

Myrio has successfully screened a large number pMHCs derived from multiple cancer targets. These include overexpressed tumor-associated proteins, viral proteins, cancer-testis antigens, oncofetal proteins, shared neoantigens, and private neoantigens. A selection of these targets are listed in the pipeline graphic below and are in the process of being evaluated in bispecific formats (anti-CD3).

03

SPA & Wellness treatments

Duis dignissim mi ut laoreet mollis. Nunc id tellus finibus, eleifend mi vel, maximus justo. Maecenas mi tortor, pellentesque a aliquam ut, fringilla.

04

Aromatherapy
consultation

Duis dignissim mi ut laoreet mollis. Nunc id tellus finibus, eleifend mi vel, maximus justo. Maecenas mi tortor, pellentesque a aliquam ut, fringilla.

Ut ultricies imperdiet sodales. Aliquam fringilla aliquam ex sit amet elementum

Proin bibendum sollicitudin feugiat. Curabitur ut egestas justo, vitae molestie ante. Integer magna purus, commodo in diam nec, pretium auctor sapien. In pulvinar, ipsum eu dignissim facilisis, massa justo varius purus, non dictum elit nibh ut massa. Nam massa erat, aliquet a rutrum eu, sagittis ac nibh. Pellentesque velit dolor, suscipit in ligula a, suscipit rhoncus dui